Literature DB >> 7086654

Extended Hildebrand solubility approach: solubility of tolbutamide, acetohexamide, and sulfisomidine in binary solvent mixtures.

A Martin, M J Miralles.   

Abstract

The extended Hildebrand approach for predicting solubilities of crystalline compounds in solvent mixtures was tested using tolbutamide, acetohexamide, and sulfisomidine in mixed solvents consisting of hexane-absolute ethanol and 95% (v/v) ethyl alcohol-aqueous buffer. The solubility of these drugs was determined at 25 +/- 0.2 degrees and then back-calculated using the adhesive energy term, W, to account for solute-solvent interaction. Solubilities were predicted within 13% for tolbutamide, 31% for acetohexamide, and 43% for sulfisomidine, and with considerably better accuracy in most solvent mixtures.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7086654     DOI: 10.1002/jps.2600710416

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Cosolvency and cosolvent polarity.

Authors:  J T Rubino; S H Yalkowsky
Journal:  Pharm Res       Date:  1987-06       Impact factor: 4.200

2.  Extended Hildebrand Solubility Approach: Prediction and Correlation of the Solubility of Itraconazole in Triacetin: Water Mixtures at 298.15°K.

Authors:  Sachin Jagdale; Rajesh B Nawale
Journal:  Turk J Pharm Sci       Date:  2020-04-24

3.  Solubility Prediction of Satranidazole in Aqueous N,N-dimethylformamide Mixtures Using Extended Hildebrand Solubility Approach.

Authors:  P B Rathi; V K Mourya
Journal:  Indian J Pharm Sci       Date:  2012-05       Impact factor: 0.975

4.  Extended hildebrand solubility approach: satranidazole in mixtures of dioxane and water.

Authors:  P B Rathi; V K Mourya
Journal:  Indian J Pharm Sci       Date:  2011-05       Impact factor: 0.975

5.  Solubility prediction of satranidazole in propylene glycol-water mixtures using extended hildebrand solubility approach.

Authors:  P B Rathi
Journal:  Indian J Pharm Sci       Date:  2011-11       Impact factor: 0.975

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.